The current Canadian Urological Association guidelines recommend that germline testing be performed in metastatic prostatic cancer patients and genomic profiling of the tumor in mCRPC patients should be performed while BRCA1/2 are among the targeted genes [36]. The gene discussed is BRCA1; the disease is metastatic prostate carcinoma.